Christine Klaskin Biography and Net Worth

Insider of Agenus

Christine M. Klaskin is the Principal Accounting Officer of Agenus Inc. Ms. Klaskin has been Vice President, Finance since October 2006. Since joining Agenus Inc. in 1996 as finance manager, Ms. Klaskin has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Ms. Klaskin is currently a member of the board of directors of American DG Energy Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.

What is Christine M. Klaskin's net worth?: The estimated net worth of Christine M. Klaskin is at least $9,896.51 as of December 12th, 2017. Ms. Klaskin owns 3,497 shares of Agenus stock worth more than $9,897 as of November 21st. This net worth estimate does not reflect any other assets that Ms. Klaskin may own. Additionally, Ms. Klaskin receives a salary of $407,440.00 as Insider at Agenus. Learn More about Christine M. Klaskin's net worth.
How old is Christine M. Klaskin?: Ms. Klaskin is currently 58 years old. There are 2 older executives and no younger executives at Agenus. The oldest executive at Agenus is Dr. Garo H. Armen Ph.D., Founder, Executive Chairman & CEO, who is 71 years old. Learn More on Christine M. Klaskin's age.
What is Christine M. Klaskin's salary?: As the Insider of Agenus Inc., Ms. Klaskin earns $407,440.00 per year. There are 2 executives that earn more than Ms. Klaskin. The highest earning executive at Agenus is Dr. Garo H. Armen Ph.D., Founder, Executive Chairman & CEO, who commands a salary of $1,340,000.00 per year. Learn More on Christine M. Klaskin's salary.
How do I contact Christine M. Klaskin?: The corporate mailing address for Ms. Klaskin and other Agenus executives is 3 FORBES ROAD, LEXINGTON MA, 02421. Agenus can also be reached via phone at (781) 674-4400 and via email at [email protected]. Learn More on Christine M. Klaskin's contact information.
Has Christine M. Klaskin been buying or selling shares of Agenus?: Christine M. Klaskin has not been actively trading shares of Agenus during the past quarter. Most recently, Christine M. Klaskin sold 556 shares of the business's stock in a transaction on Friday, September 10th. The shares were sold at an average price of $130.00, for a transaction totalling $72,280.00. Learn More on Christine M. Klaskin's trading history.
Who are Agenus' active insiders?: Agenus' insider roster includes Garo Armen (CEO), Christine Klaskin (Insider), and Steven O'Day (Insider). Learn More on Agenus' active insiders.
Are insiders buying or selling shares of Agenus?: During the last twelve months, Agenus insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $325,000.00. The most recent insider tranaction occured on February, 15th when insider Garo H Armen bought 25,000 shares worth more than $325,000.00. Insiders at Agenus own 4.6% of the company. Learn More about insider trades at Agenus.
Information on this page was last updated on 2/15/2024.

Christine M. Klaskin Insider Trading History at Agenus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/10/2021	Sell	556	$130.00	$72,280.00
12/12/2017	Sell	280	$69.20	$19,376.00	3,497

Christine M. Klaskin Buying and Selling Activity at Agenus

Agenus Company Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $2.83

$2.61

$2.87

50 Day Range

MA: $4.53

$2.57

$6.26

2 Week Range

Now: $2.83

$2.50

$19.69

Volume

280,341 shs

Average Volume

647,773 shs

Market Capitalization

$66.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Christine Klaskin Biography and Net Worth

What is Christine M. Klaskin's net worth?

How old is Christine M. Klaskin?

What is Christine M. Klaskin's salary?

How do I contact Christine M. Klaskin?

Has Christine M. Klaskin been buying or selling shares of Agenus?

Who are Agenus' active insiders?

Are insiders buying or selling shares of Agenus?